Medical Condition News

RSS

University of Missouri creates National Botanical Research Center with $7.5M NIH grant

Americans spend $25 billion a year on dietary supplement products such as herbs and other botanicals. While the Nutrition Business Journal forecasts that sales of botanical dietary supplements will increase by about 19 percent over the next five years, scientists still don't know the precise properties that make certain plants helpful or harmful to humans. Now, with a new $7.5 million grant from the National Institutes of Health, University of Missouri researchers have created a National Botanical Research Center to answer these questions.

11 Oct 2010

Progress in understanding mechanism behind photocontact allergy

What happens to sunscreens when they are exposed to sunlight? And how is the skin affected by the degradation products that form? This has been the subject of research at the University of Gothenburg and Chalmers University of Technology that will be presented at the upcoming dermatologist conference in Gothenburg.

11 Oct 2010

Research-based tip sheets provide details on breast cancer

Throughout October, National Breast Cancer Awareness Month, experts from Fred Hutchinson Cancer Research Center and its clinical care partner, the Seattle Cancer Care Alliance, are offering a series of weekly research-based tip sheets regarding a variety of topics related to breast cancer, including breast cancer prevention, screening and early detection, treatment, and survivorship.

11 Oct 2010

Yoga decreases anxiety in childhood cancer patients and their parents

A new study reports that yoga can reduce the stress of cancer diagnosis and treatment experienced by childhood cancer patients and their parents. The findings were published in the September/October 2010 edition of Journal of Pediatric Oncology Nursing, published by the Association of Pediatric Hematology/Oncology Nurses (APHON).

11 Oct 2010

Researchers identify factor that affects breast cancer patients' survival time in chemotherapy

In a study presented at the 35th Congress of the European Society for Medical Oncology (ESMO), Dr Giovanni Bernardo from Fondazione Maugeri in Pavia, Italy, presented results that suggested it may be possible to identify subsets of metastatic breast cancer patients who are likely to respond to subsequent lines of chemotherapy.

11 Oct 2010

BARDA awards $4.2 million contract to Menssana Research to develop breath test for radiation exposure

The Biomedical Advanced Research and Development Authority in the US Department of Health and Human Services has awarded Menssana Research Inc., a company with research facilities in the NJIT Enterprise Development Center, a contract for $4.2 million to develop a breath test for radiation exposure. If the contract is exercised with options, it could total $22.84 million.

11 Oct 2010

Roche, DKFZ announce research collaboration to predict cervical cancer risk

Roche Molecular Systems, Inc. and the German Cancer Research Center announced today that they have entered into a research collaboration to enable more specific prediction of a woman's risk for developing cervical cancer.

From Roche Sequencing and Life Science 11 Oct 2010

Researchers pinpoint more obesity costs in workplace

One hidden cost of obesity is lost productivity in the workplace a problem with a price tag as high as $73.1 billion, according to a new study, Agence France-Presse reports.

11 Oct 2010

Abbott to withdraw sibutramine from Canadian market

Abbott will voluntarily withdraw sibutramine from the Canadian market after discussion with Health Canada. Sibutramine is marketed by Abbott in Canada as Meridia.

11 Oct 2010

Shift work can cause cancer: Research

Shift work can cause cancer. In the new issue of the Deutsches Ärzteblatt International, Thomas C. Erren and colleagues describe the current state of knowledge in this area and point out the challenges lying ahead.

11 Oct 2010

Researchers investigate ways to minimize risk of multiple pregnancies

The complication rate during pregnancy with twins is about 40%. Women with multiple pregnancies often develop pre-eclampsia, gestational diabetes, and hemorrhages during the term of their pregnancy. Joachim W Dudenhausen from the Charité Berlin University Medicine and Rolf F Maier from Magdeburg University Medical Center, investigate which risks can be minimized by close monitoring in multiple pregnancies.

11 Oct 2010

UH researchers receive grant to develop Blue Scale device to track heart failure

As more and more medical care is provided in the home, health specialists say it is critical for people to be able to monitor themselves and make informed judgments about their health. A group of researchers in the Abramson Center for the Future of Health at the University of Houston (UH) received a $250,000 pre-seed grant from the Texas Emerging Technology Fund (ETF) for a system that assesses cardiac function in the home and alerts the user to the need for intervention.

11 Oct 2010

Takeda, Envoy enter three-year research alliance to develop schizophrenia drug

Takeda Pharmaceutical Company Limited, a global pharmaceutical company, and Envoy Therapeutics Inc., a recently formed drug discovery company, today announced that they have formed a three-year research alliance aimed at discovering drugs for schizophrenia that will have greater efficacy and safety compared to current therapies.

11 Oct 2010

Phase-II clinical trial of MLN8237 drug shows promising results for treating ovarian cancer

A drug being developed as a treatment for ovarian cancer has shown single agent activity with durable disease control in some patients in a Phase-II clinical trial, an international research group has reported.

11 Oct 2010

Abbott to withdraw Meridia medicine from the U.S. market

Abbott will voluntarily withdraw Meridia (sibutramine) from the U.S. market at the request of the U.S. Food and Drug Administration (FDA).

11 Oct 2010

First-line treatment with erlotinib drug improves progression-free survival in patients with advanced lung cancer

For patients with advanced lung cancer whose tumors carry EGFR activating mutations, first-line treatment with erlotinib nearly tripled progression-free survival compared to a standard chemotherapy combination, show results from the first prospective Phase-III study to report findings in this setting.The new results from the OPTIMAL trial were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

11 Oct 2010

Obesity can accelerate progression of acute lymphoblastic leukemia: Study

The first study to demonstrate that obesity can directly accelerate the progression of acute lymphoblastic leukemia (ALL) has been conducted at The Saban Research Institute of Childrens Hospital Los Angeles and was published in Cancer Prevention Research, on October 5, 2010.

11 Oct 2010

Smoking leads to epigenetic changes associated with cancer development: Research

For the first time, UK scientists have reported direct evidence that taking up smoking results in epigenetic changes associated with the development of cancer.The results were reported at the 35th Congress of the European Society for Medical Oncology (ESMO) in Milan, Italy.

11 Oct 2010

Researchers find new surface adaptation mechanism of biofilm-forming pathogen

Many drug-resistant infections are the result of bacterial biofilms, structured aggregates of bacteria that live on surfaces and that are extremely resistant to environmental stresses. These biofilms impact human health in many ways - cystic fibrosis, for example, is a disease in which patients die from airway bacterial biofilm infections that are invulnerable to even the most potent antibiotics.

11 Oct 2010

FDA designates NeuRx Diaphragm Pacing System as HUD device for ALS patients

Synapse Biomedical Inc. announces today that they have received the U.S. Food and Drug Administration (FDA) designation of the NeuRx Diaphragm Pacing System (DPS) as a Humanitarian Use Device (HUD) for amyotrophic lateral sclerosis (ALS) patients with a stimulatable diaphragm who are experiencing chronic hypoventilation and has now submitted for Humanitarian Device Exemption (HDE) approval.

11 Oct 2010